Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2016 / Mar / A Tale of Two Cities
Precision medicine Genetics and epigenetics Profession Omics

A Tale of Two Cities

How is fierce ambition translated into the reality of building two world-class personalized healthcare institutes?

By Michael Schubert 03/30/2016 1 min read

Share

Many experts in genetics and genomics believe that some – or all – of the above reflections are true of today’s personalized medicine. It’s easy to see how some of them apply. With technology advancing rapidly and the cost of sequencing dropping precipitously, we’re certainly experiencing the best of times in terms of our ability to explore the mysteries of the human genome. But our ability to store and interpret data still lags behind, and the more we hype the “personalized medicine revolution,” the more patients expect miracles that simply aren’t achievable. So how can we approach precision medicine from a balanced perspective? How can we optimize our resources and abilities to best serve our patients? Precision medicine is growing at an astounding pace – in the last decade, over 100 prominent new personalized diagnostic and treatment products have become available, and the Personalized Medicine Coalition has expanded more than tenfold. Even the President of the United States has launched a new Precision Medicine Initiative that funds not only grants, but the assembly of patient cohorts and the establishment of better regulatory standards. It’s clear the concept is catching on, so how can research and clinical laboratories get on board? We spoke with the leaders of two major genomic research centers to ask about their institutions, the challenges they’ve faced and continue to face, and how others can make the move to personalized medicine and contribute to the next evolution in healthcare.

Young but Powerful  By David Roth
Field of Genes  By James Broach

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

More Articles by Michael Schubert

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

A Helping Hand from AI in Prostate Cancer Diagnostics
Precision medicine
A Helping Hand from AI in Prostate Cancer Diagnostics

February 8, 2022

3 min read

Using AI to enhance personalized healthcare for patients with prostate cancer

The Ultimate Vision for Rare Disease
Precision medicine
The Ultimate Vision for Rare Disease

February 28, 2022

1 min read

Genomics and computational pathology can take rare disease diagnostics to the next level

A Light in the Darkness
Precision medicine
A Light in the Darkness

March 4, 2022

2 min read

Spectroscopic liquid biopsy testing – a new route to brain cancer diagnostics

In-House Matters
Precision medicine
In-House Matters

April 7, 2022

3 min read

Molecular pathology is complex – and the benefits of keeping it local are extensive

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.